These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 36220417)
1. [Antifibrotic therapy and its indications for interstitial pulmonary fibrosis]. Doubková M Vnitr Lek; 2022; 68(4):212-215. PubMed ID: 36220417 [TBL] [Abstract][Full Text] [Related]
2. Nintedanib: A Review in Fibrotic Interstitial Lung Diseases. Lamb YN Drugs; 2021 Apr; 81(5):575-586. PubMed ID: 33765296 [TBL] [Abstract][Full Text] [Related]
3. Progressive fibrosing interstitial lung diseases: A new concept and indication of nintedanib. Makino S Mod Rheumatol; 2021 Jan; 31(1):13-19. PubMed ID: 32964766 [TBL] [Abstract][Full Text] [Related]
9. Nintedanib in Progressive Pulmonary Fibrosis: A Systematic Review and Meta-Analysis. Ghazipura M; Mammen MJ; Herman DD; Hon SM; Bissell BD; Macrea M; Kheir F; Khor YH; Knight SL; Raghu G; Wilson KC; Hossain T Ann Am Thorac Soc; 2022 Jun; 19(6):1040-1049. PubMed ID: 35499854 [No Abstract] [Full Text] [Related]
10. Exposure-efficacy analyses of nintedanib in patients with chronic fibrosing interstitial lung disease. Schmid U; Weber B; Magnusson MO; Freiwald M Respir Med; 2021; 180():106369. PubMed ID: 33798871 [TBL] [Abstract][Full Text] [Related]
11. Efficacy of Pirfenidone and Nintedanib in Interstitial Lung Diseases Other than Idiopathic Pulmonary Fibrosis: A Systematic Review. Amati F; Stainer A; Polelli V; Mantero M; Gramegna A; Blasi F; Aliberti S Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175556 [TBL] [Abstract][Full Text] [Related]
12. Exposure-safety analyses of nintedanib in patients with chronic fibrosing interstitial lung disease. Schmid U; Weber B; Sarr C; Freiwald M BMC Pulm Med; 2021 Jul; 21(1):244. PubMed ID: 34289823 [TBL] [Abstract][Full Text] [Related]
13. Guidelines of the Polish Respiratory Society on the Diagnosis and Treatment of Progressive Fibrosing Interstitial Lung Diseases Other than Idiopathic Pulmonary Fibrosis. Piotrowski WJ; Martusewicz-Boros MM; Białas AJ; Barczyk A; Batko B; Błasińska K; Boros PW; Górska K; Grzanka P; Jassem E; Jastrzębski D; Kaczyńska J; Kowal-Bielecka O; Kucharz E; Kuś J; Kuźnar-Kamińska B; Kwiatkowska B; Langfort R; Lewandowska K; Mackiewicz B; Majewski S; Makowska J; Miłkowska-Dymanowska J; Puścińska E; Siemińska A; Sobiecka M; Soroka-Dąda RA; Szołkowska M; Wiatr E; Ziora D; Śliwiński P Adv Respir Med; 2022 Oct; 90(5):425-450. PubMed ID: 36285980 [TBL] [Abstract][Full Text] [Related]
14. Impact of antifibrotic therapy on disease progression, all-cause mortality, and risk of acute exacerbation in non-IPF fibrosing interstitial lung diseases: evidence from a meta-analysis of randomized controlled trials and prospective controlled studies. Li DY; Liu X; Huang JY; Hang WL; Yu GR; Xu Y Ther Adv Respir Dis; 2024; 18():17534666241232561. PubMed ID: 38414439 [TBL] [Abstract][Full Text] [Related]
15. Nintedanib in Asian patients with progressive fibrosing interstitial lung diseases: Results from the INBUILD trial. Inoue Y; Wells AU; Song JW; Xu Z; Kitamura H; Suda T; Okamoto M; Müller H; Coeck C; Rohr KB; Kolb M; Brown KK Respirology; 2023 May; 28(5):465-474. PubMed ID: 36642509 [TBL] [Abstract][Full Text] [Related]
16. Usefulness of Transbronchial Lung Cryobiopsy When Starting Antifibrotic Treatment and Predicting Progressive Fibrosing Interstitial Lung Disease: Descriptive Research. Takatsuka M; Yamakawa H; Takemura T; Sato S; Ohta H; Kusano K; Oba T; Kawabe R; Akasaka K; Sasaki H; Amano M; Araya J; Matsushima H Clin Respir J; 2024 Jul; 18(7):e13809. PubMed ID: 39013830 [TBL] [Abstract][Full Text] [Related]
17. [Use of antifibrotic drugs in interstitial lung disease]. Kreutz CP; Gesierich W; Behr J; Kneidinger N Dtsch Med Wochenschr; 2022 Oct; 147(21):1383-1390. PubMed ID: 36279864 [TBL] [Abstract][Full Text] [Related]
19. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. Wells AU; Flaherty KR; Brown KK; Inoue Y; Devaraj A; Richeldi L; Moua T; Crestani B; Wuyts WA; Stowasser S; Quaresma M; Goeldner RG; Schlenker-Herceg R; Kolb M; Lancet Respir Med; 2020 May; 8(5):453-460. PubMed ID: 32145830 [TBL] [Abstract][Full Text] [Related]
20. Antifibrotic Therapy: Is There a Role in Myositis-Interstitial Lung Disease? Soskis A; Hallowell R Respiration; 2021; 100(9):923-932. PubMed ID: 33951665 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]